Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY‐3+)

Patients with hepatitis C virus (HCV) genotype 3 infection, especially those with advanced liver disease, are a challenging population in urgent need of optimally effective therapies. The combination of daclatasvir (DCV; pangenotypic nonstructural protein 5A inhibitor) and sofosbuvir (SOF; nucleotid...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Hepatology
Main Authors: Leroy, Vincent, Angus, Peter, Bronowicki, Jean‐Pierre, Dore, Gregory J., Hezode, Christophe, Pianko, Stephen, Pol, Stanislas, Stuart, Katherine, Tse, Edmund, McPhee, Fiona, Bhore, Rafia, Jimenez‐Exposito, Maria Jesus, Thompson, Alexander J.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2016
Assuntos:
Rapid Communication
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5069621/
https://ncbi.nlm.nih.gov/pubmed/26822022
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hep.28473
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados